Lexaria Bioscience (LEXX) EPS (Basic) (2011 - 2026)

Lexaria Bioscience has disclosed EPS (Basic) across 16 years of filings, most recently posting $0.13 for Q1 2026.

• EPS (Basic) for Q1 2026 came in at $0.13, down 64.65% year-over-year; the trailing twelve-month figure through Feb 2026 was $1.18 (down 39.56% YoY), and the FY2025 annual result was $1.63, up 66.76% from the prior year.
• EPS (Basic) came in at $0.13 for Q1 2026 at Lexaria Bioscience, down from $0.16 in the prior quarter.
• In the past five years, EPS (Basic) ranged from a high of $0.91 in Q4 2024 to a low of -$0.61 in Q3 2022.
• The 5-year median for EPS (Basic) is $0.27 (2023), against an average of $0.23.
• Across the five-year window, EPS (Basic) slumped 350.0% in 2022 and soared 589.48% in 2024, its largest moves.
• Lexaria Bioscience's EPS (Basic) stood at $0.75 in 2022, then sank by 82.22% to $0.13 in 2023, then jumped by 589.48% to $0.91 in 2024, then plunged by 82.6% to $0.16 in 2025, then declined by 20.66% to $0.13 in 2026.
• The last three EPS (Basic) figures came in at $0.13 (Q1 2026), $0.16 (Q4 2025), and $0.37 (Q3 2025), per Business Quant data.